雅本化学(300261) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2025 was ¥334,686,849.16, a decrease of 4.59% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥1,752,000.08, an increase of 137.23% year-on-year, while the net profit after deducting non-recurring gains and losses was -¥6,110,957.58, a decrease of 62.13%[5]. - The basic earnings per share for the period was ¥0.0018, up 136.73% year-on-year[5]. - Total operating revenue for the current period reached ¥996,357,916.07, an increase of 5.0% compared to ¥939,956,746.25 in the previous period[20]. - The net profit for the current period was a loss of ¥12,777,476.47, an improvement from a loss of ¥55,695,104.00 in the previous period[21]. - The net profit attributable to the parent company was -6,916,421.61 CNY, compared to -56,719,680.51 CNY in the previous period[22]. - The total comprehensive income amounted to -9,833,502.10 CNY, down from -56,430,109.52 CNY year-over-year[22]. - The basic and diluted earnings per share were both -0.0072 CNY, compared to -0.0589 CNY in the previous period[22]. Assets and Liabilities - The total assets at the end of the reporting period were ¥4,145,198,667.21, reflecting a 3.14% increase from the end of the previous year[5]. - The total assets of the company increased to ¥4,145,198,667.21 from ¥4,019,170,670.70, marking a growth of 3.1%[17]. - Current liabilities rose to ¥1,774,722,283.44, up from ¥1,558,601,363.22, representing an increase of 13.8%[17]. - The total liabilities of the company increased to ¥2,011,507,122.69 from ¥1,875,453,209.03, reflecting a growth of 7.2%[17]. - The company's total equity decreased to ¥2,133,691,544.52 from ¥2,143,717,461.67, a decline of 0.5%[17]. Cash Flow - Cash flow from operating activities showed a net inflow of ¥5,039,810.55, a significant decrease of 94.44% compared to the previous year[5]. - Operating cash flow generated was 5,039,810.55 CNY, a significant decrease from 90,596,629.86 CNY in the previous period[24]. - Cash inflow from operating activities totaled 965,813,689.67 CNY, compared to 927,195,314.12 CNY last year[24]. - Cash outflow from operating activities was 960,773,879.12 CNY, up from 836,598,684.26 CNY in the previous period[24]. - Investment activities resulted in a net cash outflow of -82,047,974.01 CNY, compared to -88,144,766.95 CNY last year[25]. - Financing activities generated a net cash inflow of 162,729,697.72 CNY, reversing from a net outflow of -4,880,504.53 CNY in the previous period[25]. - The ending cash and cash equivalents balance was 409,464,265.46 CNY, an increase from 227,157,307.20 CNY at the end of the previous period[25]. - The company received 48,133,583.50 CNY in tax refunds, up from 39,729,171.92 CNY last year[24]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 52,662[10]. - The largest shareholder, Ningbo Yaben Holdings Co., Ltd., holds 26.75% of shares, totaling 257,729,839 shares, with 87,600,000 shares pledged[10]. - The second-largest shareholder, Wang Xinya, holds 6.75% of shares, totaling 65,000,350 shares, with 65,000,000 shares pledged[10]. - The total number of shares held by the top 10 shareholders includes significant pledges, indicating potential liquidity risks[10]. - The company has a total of 6,657,225 restricted shares that were released due to executive changes[12]. - The report indicates that there are no other known relationships among shareholders beyond those disclosed[10]. Strategic Initiatives - The company signed a strategic supply agreement with Jiangsu Hengrui Medicine Co., Ltd. on August 1, 2025, to enhance collaboration in pharmaceutical intermediates and active pharmaceutical ingredients[13]. - The company announced the termination of plans to acquire a stake in Gansu Haotian Technology Co., Ltd. on July 30, 2025[13]. - The company is focusing on innovation in the pharmaceutical CDMO business as part of its "2+X" strategy[13]. - The company has a strong emphasis on quality control and technological innovation in its operations[13]. Operational Costs - Total operating costs amounted to ¥1,026,893,621.09, slightly up from ¥1,022,711,059.09, indicating a marginal increase of 0.2%[21]. - Research and development expenses increased significantly to ¥86,247,119.60, up from ¥67,919,076.00, reflecting a growth of 27.0%[21]. Asset Management - The company reported a 334.80% increase in fair value changes, amounting to ¥10,885,655.91, primarily due to changes in other non-current financial assets[8]. - The company experienced a 16541.65% increase in asset disposal gains, totaling ¥9,670,874.25, indicating improved asset management[8]. - The company’s long-term borrowings decreased by 38.67% to ¥128,800,000.00, attributed to repayment efforts[8]. - The company’s contract liabilities increased by 88.67% to ¥15,871,737.09, indicating a rise in advance payments received[8]. - The company’s financial expenses decreased by 58.36% to ¥10,189,085.27, mainly due to the impact of exchange gains and losses[8].